PDCD1 and neoplasm: While single TIGIT blockade has demonstrated poor anti-tumour efficacy, co-blockade of TIGIT and PD-1/PD-L1 has shown significant tumour rejection (complete regression after treatment and the absence of recurrent tumour for the entire follow-up period) and prolonged overall survival in several preclinical mouse models [10].